LINE Stock Analysis: Lineage, Common Stock | NASDAQ
REIT - Industrial | NASDAQ, USA | Market Cap: 11.033m USD | 12M Return: 6% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 42.1M
Qual. Beats: 0
Rev. Trend: 79.8%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 1.9 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Lineage, Inc. (NASDAQ: LINE) is the worlds largest global temperature-controlled warehouse REIT, operating more than 500 strategically located facilities totaling approximately 88 million square feet and 3.1 billion cubic feet of capacity across North America, Europe, and Asia-Pacific. The company couples end-to-end cold chain supply chain solutions and technology with its real estate footprint, partnering with major food and beverage producers, retailers, and distributors to improve distribution efficiency, advance sustainability, and reduce supply chain waste. Lineage was incorporated in 2015, is headquartered in Novi, Michigan, and completed its IPO on July 25, 2024.
As an Industrial REIT within the GICS Real Estate sector, Lineage operates in a specialized subsector characterized by high capital intensity and significant barriers to entry, given the refrigeration infrastructure, energy demands, and regulatory requirements unique to cold storage facilities. Temperature-controlled warehousing is a critical link in the cold chain, supporting the storage and movement of frozen, refrigerated, and perishable goods across the food industry, as well as pharmaceutical and biotech customers with temperature-sensitive products.
- Cold storage occupancy and rental rates drive same-store revenue growth
- Interest rate sensitivity pressures REIT valuation and borrowing costs
- Energy and utility costs directly compress warehouse operating margins
| Net Income: -146.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA 0.58 > 1.0 |
| NWC/Revenue: -4.24% < 20% (prev -0.28%; Δ -3.95% < -1%) |
| CFO/TA 0.05 > 3% & CFO 934.0m > Net Income -146.0m |
| Net Debt (9.92b) to EBITDA (1.36b): 7.30 < 3 |
| Current Ratio: 0.85 > 1.5 & < 3 |
| Outstanding Shares: last quarter (227.0m) vs 12m ago -0.44% < -2% |
| Gross Margin: 11.08% > 18% (prev 32.69%; Δ -21.61% > 0.5%) |
| Asset Turnover: 28.35% > 50% (prev 28.26%; Δ 0.09% > 0%) |
| Interest Coverage Ratio: 0.71 > 6 (EBIT TTM 442.0m / Interest Expense TTM 623.0m) |
| A: -0.01 (Total Current Assets 1.26b - Total Current Liabilities 1.49b) / Total Assets 19.0b |
| B: -0.14 (Retained Earnings -2.61b / Total Assets 19.0b) |
| C: 0.02 (EBIT TTM 442.0m / Avg Total Assets 18.9b) |
| D: 0.81 (Book Value of Equity 8.09b / Total Liabilities 9.99b) |
| Altman-Z'' = 0.48 = B |
| DSRI: 1.07 (Receivables 917.0m/847.0m, Revenue 5.36b/5.30b) |
| GMI: 2.95 (GM 32.69% / 11.08%) |
| AQI: 0.97 (AQ_t 0.25 / AQ_t-1 0.26) |
| SGI: 1.01 (Revenue 5.36b / 5.30b) |
| TATA: -0.06 (NI -146.0m - CFO 934.0m) / TA 19.0b) |
| Beneish M = -1.22 (Cap -4..+1) = D |
As of July 12, 2026, the stock is trading at USD 43.12 with a total of 727,980 shares traded. Over the past week, the price has changed by -2.00%, over one month by -1.57%, over three months by +27.11% and over the past year by +6.03%.
Current recommended Stop Loss: 39.70 (which is 7.9% or 2.5 ATR below the current price).
Lineage, Common Stock has received a consensus analysts rating of 3.63. Therefore, it is recommended to hold LINE.
- StrongBuy: 4
- Buy: 5
- Hold: 9
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 43.2 | 0.1% |
P/E Forward = 769.2308
P/S = 2.0584
P/B = 1.2268
Revenue TTM = 5.36b USD
EBIT TTM = 442.0m USD
EBITDA TTM = 1.36b USD
Long Term Debt = 6.26b USD (from longTermDebt, last quarter)
Short Term Debt = 143.0m USD (from shortTermDebt, last quarter)
Debt = 9.99b USD (from shortLongTermDebtTotal, last quarter) + Leases 1.79b
Net Debt = 9.92b USD (calculated: Debt 9.99b - CCE 67.0m)
Enterprise Value = 21.0b USD (11.0b + Debt 9.99b - CCE 67.0m)
Interest Coverage Ratio = 0.71 (Ebit TTM 442.0m / Interest Expense TTM 623.0m)
EV/FCF = 136.9x (Enterprise Value 21.0b / FCF TTM 153.0m)
FCF Yield = 0.73% (FCF TTM 153.0m / Enterprise Value 21.0b)
FCF Margin = 2.85% (FCF TTM 153.0m / Revenue TTM 5.36b)
Net Margin = -2.72% (Net Income TTM -146.0m / Revenue TTM 5.36b)
Gross Margin = 11.08% ((Revenue TTM 5.36b - Cost of Revenue TTM 4.77b) / Revenue TTM)
Gross Margin QoQ = 14.19% (prev -34.81%)
Tobins Q-Ratio = 1.10 (Enterprise Value 21.0b / Total Assets 19.0b)
Interest Expense / Debt = 6.24% (Interest Expense 623.0m / Debt 9.99b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 349.2m (EBIT 442.0m * (1 - 21.00%))
Current Ratio = 0.85 (Total Current Assets 1.26b / Total Current Liabilities 1.49b)
Debt / Equity = 1.23 (Debt 9.99b / totalStockholderEquity, last quarter 8.09b)
Debt / EBITDA = 7.30 (Net Debt 9.92b / EBITDA 1.36b)
Debt / FCF = 64.84 (Net Debt 9.92b / FCF TTM 153.0m)
Total Stockholder Equity = 8.34b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.77% (Net Income -146.0m / Total Assets 19.0b)
RoE = -1.75% (Net Income TTM -146.0m / Total Stockholder Equity 8.34b)
RoCE = 3.03% (EBIT 442.0m / Capital Employed (Equity 8.34b + L.T.Debt 6.26b))
RoIC = 1.98% (NOPAT 349.2m / Invested Capital 17.6b)
WACC = 6.15% (E(11.0b)/V(21.0b) * Re(7.25%) + D(9.99b)/V(21.0b) * Rd(6.24%) * (1-Tc(0.21)))
Discount Rate = 7.25% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 59.68 | Cagr: 16.18%
[DCF] Terminal Value 77.97% ; FCFF base≈108.6m ; Y1≈124.5m ; Y5≈183.2m
[DCF] Fair Price = N/A (negative equity: EV 2.76b - Net Debt 9.92b = -7.16b; debt exceeds intrinsic value)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.27 | # QB: 0
Revenue Correlation: 79.80 | Revenue CAGR: 0.12% | SUE: -0.70 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.22 | Chg30d=-22.22% | Revisions=-25% | Analysts=2
EPS next Quarter (2026-09-30): EPS=-0.17 | Chg30d=+7.89% | Revisions=-25% | Analysts=2
EPS current Year (2026-12-31): EPS=-0.81 | Chg30d=-10.96% | Revisions=+0% | GrowthEPS=-534.8% | GrowthRev=+0.8%
EPS next Year (2027-12-31): EPS=-0.48 | Chg30d=+34.25% | Revisions=+25% | GrowthEPS=+40.7% | GrowthRev=+2.8%
[Analyst] Revisions Ratio: -17% (up=1, down=2)